target
fig
larg
replicas
polyprotein
encod
open
read
frame
cleav
two
viral
proteas
papainlik
proteas
plpro
proteas
produc
nonstructur
protein
nsp
rnadepend
rna
polymeras
rdrp
helicas
involv
transcript
replic
viru
fig
numer
enzym
inhibitor
target
protein
shown
anticov
activ
vitro
surfac
structur
spike
glycoprotein
particular
interest
antivir
develop
critic
role
viruscel
receptor
interact
compos
aminotermin
receptorbind
carboxytermin
membran
fusion
subunit
cleavag
proteas
site
junction
requir
activ
membran
fusion
viru
entri
syncytium
format
bind
subunit
receptorbind
domain
rbd
host
receptor
trigger
conform
chang
subunit
stalk
region
bring
viral
cell
membran
close
proxim
enabl
fusion
monoclon
antibodi
mab
subunit
rbd
fusion
inhibitor
target
subunit
potent
anticov
activ
vitro
andor
vivo
key
function
host
receptor
util
human
pathogen
cov
includ
angiotensinconvert
enzym
use
sarscov
human
cov
hcov
dipeptidyl
random
placebocontrol
studi
show
plasma
sarscov
rna
level
week
ill
higher
patient
given
hydrocortison
n
given
normal
salin
n
earli
phase
ill
suggest
earli
use
puls
methylprednisolon
might
prolong
viraemia
convalescentphas
plasma
convalescentphas
plasma
therapi
use
sever
respiratori
tract
infect
includ
sar
influenza
systemat
review
exploratori
metaanalysi
patient
sar
influenza
treat
convalescentphas
plasma
show
reduct
mortal
treatment
success
determin
avail
time
administr
among
nonrandom
sar
patient
given
convalescentphas
plasma
discharg
rate
day
patient
n
treat
within
day
ill
onset
versu
n
treat
beyond
day
treatment
use
mer
patient
ribavirin
interferon
interferon
signific
effect
clinic
outcom
casecontrol
studi
show
significantli
improv
surviv
treat
control
group
respect
p
day
day
ribavirin
interferon
retrospect
analys
show
signific
effect
clinic
outcom
ribavirin
lopinavirritonavir
interferon
host
receptor
import
determin
pathogen
tissu
tropism
host
rang
viru
mab
agent
target
host
receptor
potenti
anticov
agent
long
induc
immunopatholog
effect
anim
model
cov
enter
host
cell
use
endosom
pathway
andor
cell
surfac
nonendosom
pathway
fig
low
ph
phdepend
endosom
cystein
proteas
cathepsin
help
overcom
energet
unfavour
membran
fusion
reaction
facilit
endosom
cell
entri
cov
host
proteas
transmembran
proteas
serin
also
known
airway
trypsinlik
proteas
cleav
subunit
activ
cell
surfac
nonendosom
viru
entri
plasma
membran
inhibitor
proteas
abrog
proteolyt
cleavag
partial
block
cell
entri
merscov
also
activ
furin
serin
endoproteas
implic
process
fusion
protein
cell
entri
rna
virus
includ
hiv
avian
influenza
viru
ebola
viru
marburg
viru
flavivirus
furin
also
involv
merscov
cleavag
egress
infect
cell
monotherapi
andor
combinatori
treatment
inhibitor
host
proteas
involv
variou
cell
entri
pathway
potent
anticov
activ
vitro
evalu
anim
studi
cov
disassembl
insid
host
cell
releas
nucleocapsid
viral
rna
cytoplasm
translat
genom
rna
replic
numer
nsp
produc
cleavag
form
replicationtranscript
complex
attach
hydrophob
domain
typic
coronaviru
cov
genom
singlestrand
nonseg
rna
genom
approxim
kb
contain
cap
tail
arrang
order
replicas
gene
gene
encod
structur
protein
spike
glycoprotein
envelop
protein
e
membran
protein
nucleocapsid
protein
n
polyadenyl
tail
end
partial
overlap
open
read
frame
within
twothird
cov
genom
encod
larg
replicas
polyprotein
polyprotein
cleav
papainlik
cystein
proteas
plpro
serin
proteas
produc
nonstructur
protein
includ
rnadepend
rna
polymeras
rdrp
helicas
hel
import
enzym
involv
transcript
replic
cov
onethird
cov
genom
encod
structur
protein
e
n
essenti
viruscellreceptor
bind
virion
assembl
nonstructur
protein
accessori
protein
may
immunomodulatori
effect
particl
imag
ref
natur
publish
group
mer
middl
east
respiratori
syndrom
sar
sever
acut
respiratori
syndrom
cov
replicationtranscript
complex
limit
membran
deriv
endoplasm
reticulum
produc
typic
cov
replic
structur
includ
doublemembran
vesicl
dmv
convolut
membran
novel
agent
target
membranebound
cov
rna
synthesi
inhibit
dmv
format
broad
rang
human
anim
cov
fulllength
posit
strand
genom
rna
transcrib
form
fulllength
negativestrand
templat
synthesi
new
genom
rna
overlap
subgenom
negativestrand
templat
subgenom
mrna
synthes
translat
produc
structur
accessori
protein
helic
nucleocapsid
form
assembl
nucleocapsid
protein
n
genom
rna
interact
envelop
protein
e
membran
protein
form
assembl
virion
virion
releas
extracellular
compart
exocytosi
viral
replic
cycl
repeat
small
interf
rna
sirna
target
structur
gene
could
use
treatment
cov
infect
optim
vivo
deliveri
sirna
may
enabl
clinic
use
approach
anticov
drug
screen
two
humanpathogen
cov
known
sar
epidem
usual
caus
selflimit
upper
respiratori
tract
infect
therefor
research
research
facil
especi
involv
antivir
develop
underprepar
sarscov
suddenli
emerg
subsequ
three
gener
approach
use
discov
potenti
anticov
treatment
option
humanpathogen
cov
especi
sarscov
emerg
merscov
associ
sever
diseas
hcov
first
approach
drug
discoveri
test
exist
broadspectrum
antivir
drug
use
treat
viral
infect
use
standard
assay
measur
effect
drug
cytopath
viru
yield
plaqu
format
live
andor
pseudo
type
cov
exampl
drug
identifi
use
approach
includ
interferon
alfa
interferon
beta
interferon
gamma
ribavirin
inhibitor
cyclophilin
drug
obviou
advantag
readili
avail
known
pharmacokinet
pharmacodynam
properti
side
effect
dose
regimen
howev
specif
anticov
effect
may
associ
sever
advers
effect
second
anticov
drug
discoveri
approach
involv
screen
chemic
librari
compris
larg
number
exist
compound
databas
contain
inform
transcript
signatur
differ
cell
line
approach
provid
rapid
highthroughput
screen
mani
readili
avail
compound
evalu
antivir
assay
variou
class
drug
identifi
drug
repurpos
programm
includ
mani
import
physiolog
andor
immunolog
effect
affect
neurotransmitt
regul
oestrogen
receptor
kinas
signal
lipid
sterol
metabol
protein
process
dna
synthesi
repair
major
disadvantag
approach
although
mani
identifi
drug
exhibit
anticov
activ
vitro
clinic
use
either
associ
immunosuppress
effect
anticov
halfmaxim
effect
concentr
ec
valu
markedli
exceed
peak
serum
concentr
c
max
level
achiev
abl
therapeut
dosag
notabl
except
found
effect
nonhuman
primat
model
nonrandom
clinic
trial
antihiv
proteas
inhibitor
lopinavirritonavir
tabl
third
approach
anticov
drug
discoveri
involv
de
novo
develop
novel
specif
agent
base
genom
biophys
understand
individu
cov
exampl
includ
sirna
molecul
inhibitor
target
specif
viral
enzym
involv
viral
replic
cycl
mab
target
host
receptor
inhibitor
host
cellular
proteas
inhibitor
viru
endocytosi
host
cell
human
human
mab
target
subunit
rbd
antivir
peptid
target
subunit
fig
although
drug
potent
vitro
andor
vivo
anticov
activ
pharmacokinet
pharmacodynam
properti
sideeffect
profil
yet
evalu
anim
human
trial
furthermor
develop
candid
drug
clinic
use
therapeut
option
reliabl
deliveri
mode
patient
usual
take
year
overal
three
drug
discoveri
approach
often
use
togeth
emerg
cov
outbreak
identifi
candid
drug
compound
broadli
classifi
virusbas
hostbas
treatment
option
nucleosid
nucleotid
build
block
viral
nucleic
acid
fig
drug
target
nucleosid
nucleotid
andor
viral
nucleic
acid
gener
broadspectrum
activ
wide
rang
cov
virus
tabl
mycophenol
mofetil
antireject
drug
inhibit
inosin
monophosph
dehydrogenas
synthesi
guanin
monophosph
activ
compound
myco
phenol
acid
exhibit
antivir
activ
vitro
variou
virus
includ
hepat
b
viru
hbv
hepat
c
viru
hcv
arbovirus
mycophenol
acid
identifi
potenti
antimerscov
drug
use
highthroughput
screen
potent
antimerscov
activ
vitro
howev
subsequ
studi
nonhuman
primat
model
show
merscovinfect
common
marmoset
treat
mycophenol
mofetil
wors
outcom
sever
diseas
higher
viral
load
necropsi
lung
extrapulmonari
tissu
untreat
anim
renal
transplant
recipi
mainten
mycophenol
mofetil
therapi
also
develop
sever
fatal
mer
thu
usual
dosag
mycophenol
mofetil
monotherapi
unlik
use
prophylaxi
treatment
cov
infect
ribozym
also
known
catalyt
rna
rna
enzym
rna
molecul
catalys
specif
biochem
reaction
chimer
dnarna
hammerhead
ribozym
specif
recogn
base
sequenc
guc
present
loop
region
sarscov
mrna
substanti
reduc
express
recombin
sarscov
rna
vitro
howev
ribozym
rapidli
degrad
vivo
deliveri
method
would
optim
human
ribozym
could
becom
clinic
use
agent
target
specif
host
cell
membranebound
cov
replic
complex
also
investig
one
compound
inhibit
membranebound
cov
rna
synthesi
activ
broad
rang
cov
vitro
cell
cultur
exert
potent
anticov
activ
earli
step
viral
replic
cycl
impair
format
dmv
escap
mutant
resist
substitut
potenti
membranespan
domain
membranespan
integr
compon
cov
replic
complex
involv
dmv
format
includ
ref
emerg
resist
monitor
subsequ
vivo
studi
recent
new
class
broadspectrum
antivir
target
long
viral
doublestrand
rna
dsrna
report
exampl
dsrnaactiv
caspas
oligomer
draco
chimer
protein
viral
dsrnabind
domain
proapoptot
domain
select
induc
apoptosi
cell
contain
viral
dsrna
spare
uninfect
host
cell
draco
activ
mani
rna
virus
vitro
andor
vivo
effect
mode
draco
deliveri
achiev
broadspectrum
anticov
drug
target
highli
conserv
cov
rna
sequenc
might
becom
realiti
viral
enzym
major
enzym
protein
cov
involv
viral
replic
potenti
druggabl
target
tabl
sarscov
merscov
plpro
enzym
exhibit
proteolyt
deubiquityl
deisgyl
activ
crystallographi
facilit
character
plpro
enzym
identif
plpro
inhibitor
numer
sarscov
plpro
inhibitor
belong
differ
class
identifi
includ
smallmolecul
inhibitor
thiopurin
compound
natur
product
zinc
ion
zinc
conjug
inhibitor
naphthalen
inhibitor
howev
drug
inhibit
enzymat
activ
plpro
without
inhibit
viral
replic
vice
versa
none
valid
anim
human
studi
furthermor
plpro
inhibitor
narrowspectrum
activ
structur
differ
among
plpro
enzym
differ
cov
exampl
sarscov
plpro
inhibitor
inact
merscov
structur
differ
flexibl
block
loop
domain
plpro
enzym
sarscov
merscov
major
cov
proteas
cleav
larg
replicas
polyprotein
viral
replic
sarscov
target
numer
class
proteas
inhibitor
includ
zinc
mercuri
conjug
diol
ester
anilid
benzotriazol
biphenyl
sulfon
glutam
acid
glutamin
peptid
trifluoromethylketon
group
pyrimidinon
pyrazol
analogu
inhibitor
demonstr
broadspectrum
vitro
activ
cov
highli
similar
key
residu
substrat
recognit
enzym
among
inhibitor
readili
avail
one
lopinavir
proteas
inhibitor
use
treat
hiv
infect
usual
market
ritonavirboost
form
lopinavirritonavir
lopinavir
andor
lopinavirritonavir
anticov
activ
vitro
well
merscovinfect
nonhuman
primat
nonrandom
trial
sar
patient
postul
activ
lopinavirritonavir
contribut
least
partial
anticov
effect
remain
seen
resist
emerg
patient
hiv
infect
lopinavirritonavir
routin
use
treat
cov
infect
bind
receptorbind
domain
subunit
spike
glycoprotein
host
receptor
trigger
conform
chang
subunit
lead
fusion
viral
cell
membran
coronavirus
cov
enter
host
cell
use
endosom
pathway
andor
cell
surfac
nonendosom
pathway
endosom
cell
entri
cov
facilit
low
ph
phdepend
endosom
cystein
proteas
cathepsin
activ
cleav
subunit
host
proteas
transmembran
proteas
serin
enabl
cell
surfac
nonendosom
viru
entri
plasma
membran
middl
east
respiratori
syndrom
mer
cov
addit
activ
serin
endoproteas
furin
cov
dissembl
intracellularli
releas
nucleocapsid
viral
rna
cytoplasm
translat
larg
replicas
polyprotein
replic
genom
rna
cleav
papainlik
proteas
plpro
proteas
produc
nonstructur
protein
nsp
includ
rnadepend
rna
polymeras
rdrp
helicas
involv
transcript
replic
viru
nsp
produc
cleavag
form
replicationtranscript
complex
attach
hydrophob
domain
cov
replicationtranscript
complex
limit
membran
deriv
endoplasm
reticulum
er
produc
typic
cov
replic
structur
includ
doublemembran
vesicl
convolut
membran
fulllength
positivestrand
genom
rna
transcrib
form
fulllength
negativestrand
templat
synthesi
new
genom
rna
overlap
subgenom
negativestrand
templat
subgenom
mrna
synthes
translat
produc
structur
accessori
protein
helic
nucleocapsid
form
assembl
nucleocapsid
protein
n
genom
rna
interact
structur
protein
form
assembl
virion
releas
exocytosi
extracellular
compart
virusand
hostbas
treatment
option
highlight
red
blue
respect
positivestrand
rna
negativestrand
rna
ap
accessori
protein
cyp
cyclophilin
decrvkrcmk
decanoylargvallysargchloromethylketon
draco
doublestrand
rnaactiv
caspas
oligomer
e
envelop
protein
er
endoplasm
reticulum
ergic
endoplasm
reticulum
golgi
intermedi
compart
erk
extracellular
signalregul
kinas
membran
mab
monoclon
antibodi
mapk
mitogenactiv
protein
kinas
mpa
mycophenol
acid
mtor
mammalian
target
rapamycin
n
nucleocapsid
protein
naae
n
nfat
nuclear
factor
activ
cell
orf
open
read
frame
phosphoinositid
poli
c
polyinosin
polycytidyl
acid
rdrp
rnadepend
rna
polymeras
spike
glycoprotein
sarscov
sever
acut
respiratori
syndrom
coronaviru
sirna
small
interf
rna
sirna
evalu
publish
report
includ
sirna
direct
part
cov
genom
would
also
expect
diminish
accumul
translat
genom
upstream
subgenom
rna
adapt
permiss
ref
american
societi
microbiolog
rdrp
essenti
part
cov
replicationtranscript
complex
involv
product
genom
subgenom
rna
ribavirin
guanosin
analogu
broadspectrum
antivir
activ
use
treatment
sever
respiratori
syncyti
viru
infect
hcv
infect
viral
haemorrhag
fever
exact
mechan
action
undetermin
inhibit
mrna
cap
induct
mutat
rnadepend
viral
replic
consid
import
rna
virus
includ
cov
highdos
ribavirin
use
treat
sar
patient
benefit
unclear
exhibit
moder
antimerscov
activ
high
dose
vitro
merscovinfect
rhesu
macaqu
obviou
surviv
benefit
small
cohort
mer
patient
acycl
flexim
nucleosid
analogu
inhibit
merscov
vitro
micromolar
concentr
notabl
resist
nucleosid
analogu
due
mutat
rdrp
report
rna
virus
monitor
agent
use
treat
cov
infect
addit
nucleosid
analogu
sirna
molecul
target
sarscov
rdrp
use
inhibit
sarscov
vitro
helicas
catalys
unwind
duplex
oligonucleotid
singl
strand
atpdepend
reaction
cov
replic
cycl
helicas
inhibitor
attract
anticov
treatment
option
helicas
differ
cov
highli
homolog
base
mechan
action
cov
helicas
inhibitor
broadli
categor
two
group
first
group
includ
bananin
deriv
inhibit
unwind
atpas
activ
sarscov
helicas
result
inhibit
viral
replic
vitro
howev
toxic
result
inhibit
cellular
atpas
kinas
compound
limit
develop
human
use
second
group
cov
helicas
inhibitor
includ
compound
select
inhibit
unwind
activ
atpas
activ
cov
helicas
exampl
triazol
inhibit
broad
rang
cov
includ
sarscov
merscov
mous
hepat
viru
toxic
evalu
anim
model
membraneanchor
glycoprotein
major
immunogen
antigen
essenti
interact
viru
host
cell
receptor
fig
adopt
transfer
sera
contain
antimerscov
antibodi
block
viru
attach
acceler
viral
clearanc
lung
merscov
infect
balbc
mice
recent
transduc
adenovir
vector
express
human
ref
tabl
small
cohort
sar
patient
receiv
convalescentphas
plasma
contain
neutral
antibodi
probabl
target
cov
significantli
higher
discharg
rate
week
symptom
onset
lower
mortal
rate
howev
use
convalescentphas
plasma
therapi
emerg
cov
outbreak
limit
good
convalesc
patient
high
serum
neutral
antibodi
titr
diseas
worsen
associ
immun
enhanc
result
treatment
product
contain
low
antibodi
titr
report
cell
line
anim
studi
overcom
problem
mab
target
differ
region
sarscov
gener
immun
human
immunoglobulin
transgen
mice
clone
small
chain
variabl
region
naiv
convalesc
patient
well
immort
convalesc
sspecif
b
cell
mab
target
specif
epitop
subunit
rbd
inhibit
viruscel
receptor
bind
wherea
other
bind
subunit
interrupt
viruscel
fusion
regardless
bind
site
mechan
mab
exhibit
neutral
activ
reduc
viral
titr
vitro
andor
small
anim
model
similarli
sever
mab
target
differ
epitop
subunit
rbd
merscov
develop
monoclon
antibodi
bind
rbd
higher
affin
human
result
broader
higher
neutral
activ
vitro
importantli
combin
therapi
two
synergist
act
human
human
mab
target
noncrossresist
epitop
differ
region
may
help
reduc
frequenc
virus
mutat
escap
antibodymedi
neutral
treatment
mab
show
protect
effect
merscovinfect
human
mice
mice
transduc
adenovir
vector
express
human
ref
safeti
profil
treatment
effect
patient
evalu
antivir
peptid
target
differ
region
anoth
promis
therapeut
strategi
subunit
stalk
region
sarscov
merscov
class
viral
fusion
protein
contain
ntermin
fusion
peptid
heptad
repeat
domain
transmembran
domain
cytoplasm
domain
antivir
peptid
analog
n
terminu
pretransmembran
domain
loop
region
separ
domain
sarscov
inhibit
viru
plaqu
format
micro
molar
concentr
similarli
antivir
peptid
span
domain
merscov
inhibit
smediat
cellcel
fusion
viral
entri
cell
vitro
peptid
call
deriv
domain
administ
intranas
viral
challeng
protect
mice
mice
defici
v
j
recombinationactiv
protein
recent
transduc
adenovir
vector
express
human
merscov
infect
reduct
viral
titr
lung
protect
enhanc
combin
peptid
interferon
beta
combin
antivir
peptid
target
differ
region
subunit
may
synergist
vitro
overcom
theoret
risk
drug
resist
importantli
analog
fusion
inhibitor
enfuvirtid
bind
glycoprotein
hiv
block
membran
fusion
hiv
cell
entri
success
market
treatment
infect
primari
resist
enfuvirtid
rare
overcom
modifi
drug
contain
secondari
compensatori
mutat
exampl
success
drug
develop
includ
measur
counteract
drug
resist
therefor
favour
antivir
peptid
anticov
sirna
evalu
vivo
sirna
remain
preclin
develop
despit
report
antivir
activ
vitro
sarscovinfect
rhesu
macaqu
owe
lack
reliabl
drug
deliveri
method
human
anoth
class
anticov
agent
target
inhibit
cov
entri
carbohydratebind
agent
griffithsin
antivir
protein
origin
isol
red
alga
griffithsia
spp
bind
specif
oligo
saccharid
viral
surfac
glycoprotein
hiv
glycoprotein
inhibit
broad
rang
cov
includ
sarscov
vitro
sarscovinfect
mice
optim
deliveri
mode
safeti
profil
agent
human
evalu
viral
envelop
membran
nucleocapsid
accessori
protein
e
n
accessori
protein
essenti
virion
assembl
may
also
addit
function
suppress
host
immun
respons
facilit
viral
replic
exampl
accessori
protein
possibl
also
accessori
protein
merscov
exhibit
interferon
antagonist
activ
sarscov
n
act
viral
suppressor
rna
silenc
suppress
rna
interfer
trigger
either
short
hairpin
rna
sirna
tabl
sirna
target
e
n
sarscov
inhibit
viral
replic
vitro
howev
similar
anticov
sirna
none
sirna
readi
human
use
better
deliveri
method
becom
avail
altern
increas
number
agent
target
specif
bind
site
function
protein
gener
crystallographi
function
assay
exampl
includ
viroporin
inhibitor
hexamethylen
amilorid
reduc
ion
channel
activ
e
sarscov
bind
distinct
ribonucleotidebind
pocket
ntermin
domain
n
ref
howev
agent
like
narrowspectrum
bind
site
function
protein
uniqu
individu
cov
novel
lipophil
thiazolidin
deriv
membranebind
photosensit
produc
singlet
oxygen
molecul
induc
chang
properti
lipid
membran
prevent
fusion
viral
target
cell
membran
exhibit
broadspectrum
activ
numer
envelop
virus
may
activ
cov
broadspectrum
host
innat
immun
respons
host
innat
interferon
respons
crucial
control
viral
replic
infect
although
cov
abl
suppress
interferon
respons
immun
evas
remain
suscept
interferon
treatment
vitro
interferon
respons
augment
administr
recombin
interferon
interferon
induc
tabl
recombin
interferon
alfa
interferon
beta
inhibit
replic
sarscov
merscov
vitro
anim
model
variou
combin
interferon
alfa
interferon
beta
antivir
ribavirin
andor
lopinavirritonavir
use
treat
patient
sar
mer
overal
combin
treatment
consist
interferon
ribavirin
consist
improv
outcom
appar
discrep
vitro
find
vivo
outcom
may
relat
high
ec
c
max
ratio
drug
delay
symptom
onset
drug
administr
delay
especi
relev
mer
patient
much
shorter
median
time
interv
symptom
onset
death
sar
patient
use
recombin
interferon
lowest
ec
c
max
ratio
merscov
among
test
prepar
recombin
interferon
evalu
combin
effect
antivir
clinic
trial
earli
stage
infect
polyinosin
polycytidyl
acid
poli
c
synthet
analogu
dsrna
strongli
induc
type
interferon
substanti
reduc
merscov
load
balbc
mice
transduc
adenovir
vector
express
human
shortli
poli
c
administr
although
effect
standard
cell
cultur
protect
assay
publish
intramuscular
inject
poli
c
stabil
polyllysin
carboxymethylcellulos
seem
well
toler
patient
malign
glioma
phase
ii
clinic
trial
nitazoxanid
anoth
potent
type
interferon
induc
use
human
parasit
infect
synthet
nitrothiazolylsalicylamid
deriv
exhibit
broadspectrum
antivir
activ
rna
dna
virus
includ
canin
cov
influenza
virus
hbv
hcv
hiv
rotaviru
noroviru
flavivirus
evalu
phase
ii
phase
iii
clinic
trial
treatment
hcv
infect
influenza
good
safeti
profil
innat
immunomodul
antisarscov
effect
anim
model
includ
antimicrobi
peptid
rhesu
protein
cage
nanoparticl
elicit
host
immun
respons
induc
bronchusassoci
lymphoid
tissu
combin
use
interferon
induc
innat
immuno
modul
effect
antivir
agent
may
synergist
evalu
anim
model
addit
direct
potenti
interferon
respons
cell
signal
pathway
identifi
potenti
anticov
treatment
target
tabl
cyclophilin
interact
sarscov
modul
calcineurin
pathway
import
cellmedi
adapt
immun
respons
calcineurin
inhibitor
cyclosporin
inhibit
broad
rang
cov
vitro
howev
clinic
applic
limit
immunosuppress
effect
high
ec
c
max
ratio
standard
therapeut
dosag
antivir
activ
newer
nonimmunosuppress
calcineurin
inhibitor
activ
evalu
sarscov
merscov
poli
similarli
agent
modul
cellular
signal
pathway
kinas
signal
pathway
inhibitor
also
exhibit
anticov
activ
commerci
avail
howev
toxic
may
limit
use
patient
sever
cov
infect
cov
util
specif
host
factor
viru
entri
replic
fig
host
receptor
target
specif
monoclon
polyclon
antibodi
peptid
function
inhibitor
tabl
exampl
mab
inhibit
merscov
cell
entri
vitro
recombin
human
mab
seem
well
toler
patient
advanc
solid
tumour
treatment
sarscov
smallmolecul
entri
inhibitor
n
naae
inhibit
catalyt
activ
sarscov
smediat
cellcel
fusion
vitro
synthet
peptid
analog
critic
segment
also
antisarscov
activ
micromolar
concentr
vitro
howev
none
receptordirect
compound
yet
test
patient
cov
infect
anticov
activ
like
narrowspectrum
differ
cov
util
differ
host
cell
receptor
furthermor
risk
immunopatholog
must
assess
especi
given
multipl
essenti
biolog
immunolog
function
receptor
entri
cov
host
cell
via
endo
somal
andor
cell
surfac
pathway
facilit
host
proteas
cleav
activ
cathepsin
cystein
proteas
involv
endosom
pathway
inhibit
cathepsin
inhibitor
relat
vinylsulfon
analogu
angiotensinconvert
enzym
adenoviru
type
express
human
dipeptidyl
peptidas
atpas
subunit
c
max
peak
serum
concentr
cov
coronaviru
decrvkrcmk
decanoylargvallysargchloromethylketon
dipeptidyl
peptidas
ec
halfmaxim
effect
concentr
erk
extracellular
signalregul
kinas
hbv
hepat
b
viru
hcov
human
coronaviru
hcv
hepat
c
viru
hpv
human
papillomaviru
iav
influenza
viru
ibv
influenza
b
viru
jev
japanes
enceph
viru
mab
monoclon
antibodi
mapk
mitogenactiv
protein
kinas
mer
middl
east
respiratori
syndrom
mtor
mammalian
target
rapamycin
naae
n
nfat
nuclear
factor
activ
cell
nonstructur
protein
phosphoinositid
pif
parainfluenza
viru
pkr
protein
kinas
r
poli
c
polyinosin
polycytidyl
acid
rsv
respiratori
syncyti
viru
spike
glycoprotein
sar
sever
acut
respiratori
syndrom
transmembran
proteas
serin
vsv
vesicular
stomat
viru
yfv
yellow
fever
viru
compound
seem
safe
effect
variou
parasit
infect
anim
model
broadspectrum
activ
envelop
rna
virus
cov
sarscov
merscov
filovirus
ebola
marburg
virus
paramyxovirus
serin
proteas
mediat
cell
surfac
entri
pathway
camostat
mesyl
synthet
lowmolecularweight
serin
proteas
inhibitor
use
treat
chronic
pancreat
human
minim
side
effect
molecul
inhibit
sarscov
merscov
vitro
improv
surviv
sarscovinfect
mice
furin
anoth
ubiquit
express
host
proteas
also
import
merscov
smediat
entri
block
furin
decanoylargvallysargchloromethylketon
inhibit
merscov
entri
cellcel
fusion
vitro
anoth
group
candid
anticov
drug
target
endocytosi
cov
cell
entri
chlorpromazin
antipsychot
drug
use
treatment
schizophrenia
also
affect
assembl
clathrinco
pit
plasma
membran
activ
hcv
alphavirus
numer
cov
includ
sarscov
merscov
vitro
cardioton
steroid
bind
sodium
potassiumtransport
atpas
subunit
ouabain
bufalin
also
inhibit
clathrinmedi
endocytosi
merscov
nanomolar
concentr
howev
use
clathrinmedi
endocytosi
inhibitor
patient
cov
infect
limit
either
high
ec
c
max
ratio
toxic
altern
endocytosi
also
suppress
high
ph
chloroquin
antimalari
drug
sequest
proton
lysosom
increas
intracellular
ph
broadspectrum
antivir
activ
numer
cov
sarscov
merscov
rna
virus
vitro
howev
substanti
reduc
viral
replic
sarscovinfect
mice
possibl
cell
surfac
pathway
simultan
block
anticov
effect
pharmacokinet
pharmacodynam
profil
toxic
combin
differ
proteas
endocytosi
inhibitor
target
differ
cell
entri
pathway
evalu
vivo
rapid
diagnost
effect
vaccin
often
complementari
antivir
treatment
control
epidem
caus
emerg
virus
box
although
new
human
sar
case
year
sporad
case
cluster
mer
continu
occur
middl
east
owe
persist
zoonot
sourc
endem
area
case
spread
region
effect
merscov
vaccin
essenti
interrupt
chain
transmiss
anim
reservoir
infect
human
suscept
host
liveattenu
vaccin
previous
evalu
anim
model
sar
might
associ
dissemin
infect
immunocompromis
patient
inactiv
vaccin
might
associ
immunopatholog
anim
challeng
unfavour
approach
mer
vaccin
develop
substanti
proport
patient
sever
mer
comorbid
system
immunocompromis
condit
vaccin
strategi
mer
use
dna
plasmid
viral
vector
nanoparticl
viruslik
particl
recombin
protein
subunit
develop
evalu
anim
model
avail
safe
effect
merscov
vaccin
dromedari
camel
nonimmun
individu
high
risk
camel
contact
endem
region
middl
east
greater
horn
africa
would
import
measur
control
ongo
epidem
anim
model
test
anticov
drug
suitabl
anim
model
especi
import
test
anticov
drug
drug
use
human
contrast
limit
number
anim
model
establish
mild
infect
caus
variou
small
anim
nonhuman
primat
model
evalu
studi
pathogenesi
treatment
sar
mer
identif
function
receptor
sarscov
merscov
respect
essenti
develop
anim
model
repres
sever
human
diseas
number
differ
nonhuman
primat
found
permiss
sarscov
none
consist
reproduc
characterist
sever
human
diseas
mortal
observ
model
predominantli
use
fulfil
koch
postul
small
anim
includ
young
age
balbc
mice
knockout
mice
defici
b
andor
nk
cell
golden
syrian
hamster
ferret
could
product
infect
sarscov
develop
clinic
appar
diseas
best
avail
small
anim
model
sar
util
transgen
mice
express
human
andor
mouseadapt
sarscov
strain
capabl
caus
lethal
diseas
mice
limit
avail
mice
mouseadapt
viru
strain
remain
major
obstacl
test
antisarscov
drug
similar
sar
nonhuman
primat
model
also
use
fulfil
koch
postul
investig
pathogenesi
mer
rhesu
macaqu
develop
mild
selflimit
diseas
optim
evalu
treatment
mer
contrast
merscovinfect
common
marmoset
develop
dissemin
fatal
infect
close
resembl
sever
human
diseas
howev
avail
common
marmoset
limit
experi
small
primat
technic
demand
therefor
small
anim
model
mer
evalu
unlik
sarscov
small
anim
includ
balbc
mice
golden
syrian
hamster
ferret
rabbit
suscept
merscov
infect
intranas
inocul
adenovir
vector
express
human
follow
merscov
inocul
novel
method
rapidli
render
mice
suscept
merscov
infect
diseas
rel
mild
confin
respiratori
tract
transgen
mice
express
human
develop
sever
pulmonari
dissemin
infect
current
best
avail
small
anim
model
mer
potenti
antimerscov
treatment
option
identifi
vitro
antivir
assay
evalu
transgen
mice
number
virolog
patientassoci
factor
pose
major
challeng
clinic
develop
novel
anticov
drug
first
cov
one
divers
rapidli
mutat
group
virus
novel
cov
emerg
repeatedli
unpredict
time
therefor
anticov
drug
specif
target
replic
apparatu
exist
cov
may
effect
anoth
novel
cov
especi
applic
viral
enzym
inhibitor
mab
antivir
peptid
target
well
agent
target
host
cell
receptor
second
limit
number
anim
model
avail
infect
caus
even
sar
mer
experi
use
suitabl
anim
model
mice
transgen
encod
nonhuman
primat
avail
design
research
biosafeti
level
laboratori
experi
technic
demand
last
import
mild
clinic
sever
infect
caus
togeth
absenc
new
sar
case
made
recruit
patient
clinic
trial
difficult
reduc
incent
pharmaceut
compani
develop
specif
antivir
drug
cov
infect
continu
threat
merscov
global
health
secur
year
first
discoveri
present
golden
opportun
tackl
current
obstacl
develop
new
anticov
drug
demonstr
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
epidem
rapid
accur
laboratori
diagnosi
essenti
clinic
manag
epidemiolog
control
coronaviru
cov
infect
realtim
revers
transcript
rt
pcr
assay
quantifi
viral
load
facilit
studi
viral
shed
pattern
optim
treatment
infect
control
strategi
peak
viral
load
sar
found
occur
day
symptom
onset
help
predict
time
clinic
deterior
need
intens
support
care
pointofcar
nucleic
amplif
test
rtloopmedi
isotherm
amplif
rtisotherm
recombinas
polymeras
amplif
suitabl
field
evalu
especi
resourcelimit
area
similarli
assay
detect
abundantli
express
cov
antigen
nucleocapsid
protein
use
fast
highthroughput
laboratori
diagnosi
without
requir
biosafeti
level
contain
rapid
avail
complet
genom
sequenc
human
anim
cov
minim
time
requir
design
new
rtpcr
assay
sourc
identif
molecular
surveil
emerg
cov
well
illustr
mer
epidem
highli
sensit
specif
rtpcr
assay
target
uniqu
gene
region
region
upstream
envelop
e
gene
upe
region
quickli
develop
complet
genom
sequenc
merscov
strain
isol
human
becam
avail
compar
genom
studi
quickli
identifi
bat
camel
carri
cov
highli
similar
merscov
strain
isol
human
two
anim
determin
like
cov
reservoir
continu
surveil
analysi
merscov
genom
obtain
patient
anim
differ
area
middl
east
import
detect
mutat
may
increas
abil
viru
effici
transmit
person
person
data
analys
sequenc
small
rna
use
lock
nucleic
acid
probe
allow
develop
new
assay
target
short
abundantli
express
gene
region
cov
genom
leader
sequenc
increas
number
complet
cov
genom
diagnost
gene
target
enabl
develop
multiplex
assay
simultan
detect
multipl
cov
multipl
gene
target
particular
cov
increas
use
multiplex
assay
clinic
laboratori
worldwid
enhanc
understand
chang
epidemiolog
cov
infect
enabl
stratif
atrisk
patient
contact
group
earli
treatment
prophylaxi
addit
improv
acut
clinic
diagnosi
diagnost
advanc
facilit
aspect
control
cov
epidem
anticov
drug
develop
isol
infecti
viru
particl
clinic
specimen
cell
cultur
limit
role
acut
diagnosi
cov
infect
humanpathogen
cov
either
difficult
danger
cultur
nevertheless
recent
advanc
enhanc
use
cov
pathogenesi
studi
import
identifi
new
treatment
target
previous
uncultur
isol
primari
differenti
human
tracheal
bronchial
epitheli
cell
human
alveolar
type
ii
cell
cultur
airliquid
interfac
ex
vivo
organ
cultur
enabl
identif
import
viral
host
factor
involv
sever
pulmonari
extrapulmonari
manifest
sar
mer
number
avail
human
anim
cell
line
variou
organ
increas
provid
insight
tissu
speci
tropism
similarli
detect
specif
anticov
antibodi
pair
acut
convalesc
sera
sampl
mainli
use
seroepidemiolog
studi
contact
trace
acut
diagnosi
novel
assay
spike
glycoprotein
pseudoparticl
neutral
assay
requir
biosafeti
level
contain
enabl
highthroughput
antibodi
detect
largescal
seroepidemiolog
studi
outbreak
investig
prudent
wellorgan
multidisciplinari
intern
collabor
network
consist
clinician
virologist
drug
develop
coupl
polit
commit
form
carri
clinic
trial
use
anticov
drug
alreadi
shown
safe
effect
vitro
andor
anim
model
despit
report
larg
number
virusbas
hostbas
treatment
option
potent
vitro
activ
sar
mer
like
fulfil
potenti
clinic
set
forese
futur
drug
one
major
limit
prevent
proceed
beyond
vitro
stage
first
mani
drug
high
ec
c
max
ratio
clinic
relev
dosag
exampl
drug
includ
cyclosporin
chlorpromazin
interferon
alfa
second
sever
side
effect
caus
immunosuppress
exampl
use
highdos
ribavirin
may
associ
haemolyt
anaemia
neutropenia
teratogen
cardiorespiratori
distress
merscovinfect
common
marmoset
treat
mycophenol
mofetil
develop
fatal
infect
even
higher
viral
load
lung
extrapulmonari
tissu
untreat
control
agent
target
host
signal
pathway
receptor
may
induc
immunopatholog
furthermor
lack
reliabl
balbcj
mice
vaccin
merscov
sencod
dna
develop
neutral
antimerscov
antibodi
neutral
antibodi
titr
boost
vaccin
protein
rhesu
macaqu
vaccin
sequenti
merscov
sencod
dna
protein
reduc
ct
scan
abnorm
vaccin
balbc
mice
andor
rabbit
develop
neutral
antibodi
protect
effect
may
enhanc
combin
differ
adjuv
nonneutr
epitop
fulllength
sbase
vaccin
may
induc
antibodymedi
diseas
enhanc
ad
adenoviru
cov
coronaviru
ct
computer
tomographi
e
envelop
protein
human
dipeptidyl
peptidas
igg
immunoglobulin
g
mer
middl
east
respiratori
syndrom
mva
modifi
vaccinia
viru
ankara
rbd
receptorbind
domain
rrbd
recombin
rbd
spike
glycoprotein
sar
sever
acut
respiratori
syndrom
rbd
fc
rbd
fuse
antibodi
crystalliz
fragment
fc
amino
acid
residu
subunit
fuse
antibodi
crystalliz
fragment
vee
venezuelan
equin
enceph
vrp
viru
replicon
particl
drug
deliveri
method
vivo
particularli
problemat
sirna
agent
previous
use
human
look
ahead
feasibl
option
evalu
clinic
trial
ongo
mer
epidem
includ
monotherapi
combin
therapi
includ
lopinavirritonavir
interferon
andor
mab
antivir
peptid
target
merscov
agent
protect
effect
mer
nonhuman
primat
mous
model
moreov
either
market
drug
case
lopinavirritonavir
interferon
success
develop
infect
palivizumab
use
respiratori
syncyti
viru
infect
enfuvirtid
use
hiv
infect
long
term
develop
novel
broadspectrum
pancov
antivir
drug
activ
wide
rang
cov
may
becom
ultim
treatment
strategi
circul
emerg
cov
infect
